Pediatric tracheal typical carcinoid:one case report with a review of literature

References:

[1] Shah S, Gosain R, Groman A, et al.Incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States[J].Cancers (Basel), 2021, 13(8):1753.DOI:10.3390/cancers13081753.
[2] Dasari A, Shen C, Halperin D, et al.Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States[J].JAMA Oncol, 2017, 3(10):1335-1342.DOI:10.1001/jamaoncol.2017.0589.
[3] Korse CM, Taal BG, van Velthuysen MLF, et al.Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade:experience of two decades of cancer registry[J].Eur J Cancer, 2013, 49(8):1975-1983.DOI:10.1016/j.ejca.2012.12.022.
[4] WHO Classification of Tumours Editorial Board.Thoracic tumours[M].Lyon:International Agency for Research on Cancer, 2021.
[5] 夏德林, 陆月明.肺神经内分泌肿瘤的诊断与治疗进展[J].国际呼吸杂志, 2018, 38(15):1186-1189.DOI:10.3760/cma.j.issn.1673-436X.2018.15.015. Xia DL, Lu YM.Progress on diagnosis and treatment of lung neuroendocrine tumors[J].Int J Respir, 2018, 38(15):1186-1189.DOI:10.3760/cma.j.issn.1673-436X.2018.15.015.
[6] 肺神经内分泌肿瘤病理诊断共识专家组.肺神经内分泌肿瘤病理诊断共识[J].中华病理学杂志, 2017, 46(1):9-13.DOI:10.3760/cma.j.issn.0529-5807.2017.01.003. Pathologic Consensus of Pulmonary Neuroendocrine Tumors Group.Pathologic consensus of pulmonary neuroendocrine tumors[J].Chin J Pathol, 2017, 46(1):9-13.DOI:10.3760/cma.j.issn.0529-5807.2017.01.003.
[7] 中国临床肿瘤学会神经内分泌肿瘤专家委员会.中国肺和胸腺神经内分泌肿瘤专家共识[J].中华肿瘤杂志, 2021, 43(10):989-1000.DOI:10.3760/cma.j.cn112152-20210719-00522. Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology.Chinese expert consensus on lung and thymus neuroendocrine neoplasms[J].Chin J Oncol, 2021, 43(10):989-1000.DOI:10.3760/cma.j.cn112152-20210719-00522.
[8] Kneuertz PJ, Kamel MK, Stiles BM, et al.Incidence and prognostic significance of carcinoid lymph node metastases[J].Ann Thorac Surg, 2018, 106(4):981-988.DOI:10.1016/j.athoracsur.2018.05.044.
[9] Zhu MJ, Fuentes HE, Westin GFM, et al.Management of bronchopulmonary carcinoid:NCDB database analysis[J].J Clin Oncol, 2020, 38(S15):e21007.DOI:10.1200/JCO.2020.38.15_suppl.e21007.
[10] Brown LM, Cooke DT, Jett JR, et al.Extent of resection and lymph node assessment for clinical stage T1aN0M0 typical carcinoid tumors[J].Ann Thorac Surg, 2018, 105(1):207-213.DOI:10.1016/j.athoracsur.2017.07.049.
[11] García-Yuste M, Matilla JM, Cueto A, et al.Typical and atypical carcinoid tumours:analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung[J].Eur J Cardiothorac Surg, 2007, 31(2):192-197.DOI:10.1016/j.ejcts.2006.11.031.
[12] Nussbaum DP, Speicher PJ, Gulack BC, et al.Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors[J].Ann Thorac Surg, 2015, 99(2):428-434.DOI:10.1016/j.athoracsur.2014.08.030.
[13] Daddi N, Schiavon M, Filosso PL, et al.Prognostic factors in a multicentre study of 247 atypical pulmonary carcinoids[J].Eur J Cardiothorac Surg, 2014, 45(4):677-686.DOI:10.1093/ejcts/ezt470.
[14] Asamura H, Kameya T, Matsuno Y, et al.Neuroendocrine neoplasms of the lung:a prognostic spectrum[J].J Clin Oncol, 2006, 24(1):70-76.DOI:10.1200/JCO.2005.04.1202.
[15] Ferguson MK, Landreneau RJ, Hazelrigg SR, et al.Long-term outcome after resection for bronchial carcinoid tumors[J].Eur J Cardiothorac Surg, 2000, 18(2):156-161.DOI:10.1016/s1010-7940(00)00493-0.
[16] 朱锋锋, 高文, 陈昶.肺类癌外科治疗的疗效分析[J].中华外科杂志, 2009, 47(2):152-153.DOI:10.3760/cma.j.issn.0529-5815.2009.02.024. Zhu FF, Gao W, Chen C.Analysis of curative effect of surgical treatment of lung carcinoid[J].Chin J Surg, 2009, 47(2):152-153.DOI:10.3760/cma.j.issn.0529-5815.2009.02.024.
[17] Filosso PL, Guerrera F, Falco NR, et al.Anatomical resections are superior to wedge resections for overall survival in patients with Stage 1 typical carcinoids[J].Eur J Cardiothorac Surg, 2019, 55(2):273-279.DOI:10.1093/ejcts/ezy250.